Halozyme Therapeutics Earnings & Forecasts

Halozyme Therapeutics (HALO) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Aug 6, 2026	$2.28	$1.80	26.7 %
Q1	May 11, 2026	$1.60	$1.51	5.96 %
Q4	Feb 17, 2026	$-0.24	$2.15	-111.2 %
Q3	Nov 3, 2025	$1.72	$1.58	8.86 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Aug 6, 2026	$481.00M	$405.15M	18.7 %
Q1	May 11, 2026	$376.71M	$358.79M	4.99 %
Q4	Feb 17, 2026	$451.77M	$447.13M	1.04 %
Q3	Nov 3, 2025	$354.26M	$338.29M	4.72 %

Halozyme Therapeutics Guidance

Halozyme Therapeutics (HALO) は、8 6, 2026 年に fiscal year 2026 のガイダンスを最後に発表しました。同社は 1 株当たり利益を $8.65 - $9 の範囲と予想し、コンセンサス EPS 予想は $8.02 でした。Halozyme Therapeutics も、この期間の売上高を $1.83B - $1.91B の範囲と予想しました。

以前のガイダンスと比較すると、Halozyme TherapeuticsはEPS見通しを以前の範囲である引き上げから$7.75 - $8.25に引き上げました。売上高については、同社は売上高予測を以前の範囲である引き上げから$1.71B - $1.81Bに引き上げました。

Halozyme Therapeuticsは、25から11 8, 2022の間に8 6, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 14 times, reflecting management's growing confidence in business performance.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$1.80	$1.51	$2.15	$1.58
Actual	$2.28	$1.60	$-0.24	$1.72
Surprise	+26.7%	+5.96%	-111.2%	+8.86%
Revenue
Estimate	$405.2M	$358.8M	$447.1M	$338.3M
Actual	$481.0M	$376.7M	$451.8M	$354.3M
Surprise	+18.7%	+4.99%	+1.04%	+4.72%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$2.26	$2.57	$1.78	$2.04
Revenue
Consensus	$481.6M	$538.4M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.84 by 23.91 percent. This is a 48.05 percent increase over earnings of $1.54 per share

Benzinga Newsdesk

PRO
Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 Est; Raises FY2026 Sales Guidance from $1.710B-$1.810B to $1.835B-$1.910B vs $1.773B Est

Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 analyst estimate. Raises FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.835 billion-$1.910

Benzinga Newsdesk

PRO
Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est

Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810

Benzinga Newsdesk

Halozyme Therapeutics Inc